Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCL
An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.
Armin Ghobadi, MD, on How to Interpret Preliminary Data in Patients with DLBCL
Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.
Armin Ghobadi, MD, Discusses Trials Needed to Build on Blinatumomab Pilot Study Data
Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.
Ghobadi on the Correlation Between CD8/CD4 Ratio and Responses to Blinatumomab in Patients With DLBCL
Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.
Armin Ghobadi, MD, on Blinatumomab Consolidation Post Stem-Cell Transplant for DLBCL
Research from a pilot trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting found above average complete response and disease-free survival rates for patients with DLBCL.